BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 3161945)

  • 1. Factor I co-factor activity of CR1 overcomes the protective effect of IgG on covalently bound C3b residues.
    Fries LF; Prince GM; Gaither TA; Frank MM
    J Immunol; 1985 Oct; 135(4):2673-9. PubMed ID: 3161945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. C3b covalently bound to IgG demonstrates a reduced rate of inactivation by factors H and I.
    Fries LF; Gaither TA; Hammer CH; Frank MM
    J Exp Med; 1984 Dec; 160(6):1640-55. PubMed ID: 6239898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unique role of the complement receptor CR1 in the degradation of C3b associated with immune complexes.
    Medof ME; Iida K; Mold C; Nussenzweig V
    J Exp Med; 1982 Dec; 156(6):1739-54. PubMed ID: 7175439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generation of three different fragments of bound C3 with purified factor I or serum. II. Location of binding sites in the C3 fragments for factors B and H, complement receptors, and bovine conglutinin.
    Ross GD; Newman SL; Lambris JD; Devery-Pocius JE; Cain JA; Lachmann PJ
    J Exp Med; 1983 Aug; 158(2):334-52. PubMed ID: 6224880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interaction of vaccinia virus complement control protein with human complement proteins: factor I-mediated degradation of C3b to iC3b1 inactivates the alternative complement pathway.
    Sahu A; Isaacs SN; Soulika AM; Lambris JD
    J Immunol; 1998 Jun; 160(11):5596-604. PubMed ID: 9605165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phosphorylation of C3 by a casein kinase released from activated human platelets increases opsonization of immune complexes and binding to complement receptor type 1.
    Nilsson-Ekdahl K; Nilsson B
    Eur J Immunol; 2001 Apr; 31(4):1047-54. PubMed ID: 11298329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulatory proteins for the activated third and fourth components of complement (C3b and C4b) in mice. II. Identification and properties of complement receptor type 1 (CR1).
    Kinoshita T; Lavoie S; Nussenzweig V
    J Immunol; 1985 Apr; 134(4):2564-70. PubMed ID: 3156184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differences between the binding sites of the complement regulatory proteins DAF, CR1, and factor H on C3 convertases.
    Pangburn MK
    J Immunol; 1986 Mar; 136(6):2216-21. PubMed ID: 2419425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of the C3b receptor-binding domain in third component of complement.
    Becherer JD; Lambris JD
    J Biol Chem; 1988 Oct; 263(28):14586-91. PubMed ID: 2971659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Binding and catabolism of aggregated immunoglobulins containing C3b by U937 cells.
    Mehta RL; Takahashi H; Rudick RA; Knutson DW
    J Immunol; 1986 Mar; 136(5):1765-71. PubMed ID: 2936811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inefficient binding of IgM immune complexes to erythrocyte C3b-C4b receptors (CR1) and weak incorporation of C3b-iC3b into the complexes.
    Kávai M; Rasmussen JM; Baatrup G; Zsindely A; Svehag SE
    Scand J Immunol; 1988 Jul; 28(1):123-8. PubMed ID: 2969612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of human factor I and C3b receptor in the cleavage of surface-bound C3bi molecules.
    Medicus RG; Melamed J; Arnaout MA
    Eur J Immunol; 1983 Jun; 13(6):465-70. PubMed ID: 6222909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Common binding region of complement factors B, H and CR1 on C3b revealed by monoclonal anti-C3d.
    Koistinen V; Wessberg S; Leikola J
    Complement Inflamm; 1989; 6(4):270-80. PubMed ID: 2527715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The binding of complement component C3 to antibody-antigen aggregates after activation of the alternative pathway in human serum.
    Gadd KJ; Reid KB
    Biochem J; 1981 May; 195(2):471-80. PubMed ID: 7316962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of granulocyte histaminase release by particle-bound complement C3 cleavage products (C3b, C3bi) and IgG.
    Melamed J; Medicus RG; Arnaout MA; Colten HR
    J Immunol; 1983 Jul; 131(1):439-44. PubMed ID: 6223078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune complex binding efficiency of erythrocyte complement receptor 1 (CR1).
    Madi N; Paccaud JP; Steiger G; Schifferli JA
    Clin Exp Immunol; 1991 Apr; 84(1):9-15. PubMed ID: 1826650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Release of immune complexes bound to erythrocyte complement receptor (CR1), with particular reference to the role of factor I.
    Jepsen HH; Svehag SE; Jensenius JC; Sim RB
    Scand J Immunol; 1986 Aug; 24(2):205-13. PubMed ID: 2944215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Physiologic inactivation of fluid phase C3b: isolation and structural analysis of C3c, C3d,g (alpha 2D), and C3g.
    Davis AE; Harrison RA; Lachmann PJ
    J Immunol; 1984 Apr; 132(4):1960-6. PubMed ID: 6607952
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of proteolytic activity of complement factor I by pH: C3b/C4b receptor (CR1) and membrane cofactor protein (MCP) have different pH optima for factor I-mediated cleavage of C3b.
    Seya T; Okada M; Nishino H; Atkinson JP
    J Biochem; 1990 Feb; 107(2):310-5. PubMed ID: 2141838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Formation of covalently linked C3-C3 dimers on IgG immune aggregates.
    Barrio E; Antón LC; Marqués G; Sánchez A; Vivanco F
    Eur J Immunol; 1991 Feb; 21(2):343-9. PubMed ID: 1999223
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.